rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    INO
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Inovio Pharmaceuticals Prepares First Product Launch After VOCERYQ FDA Approval
      4h agoYahoo FinanceINO
      INOVIO Submits Conditional Marketing Authorization Application to European Medicines Agency for VOCERYQ™ in Adults with Recurrent Respiratory Papillomatosis

      INOVIO (NASDAQ: INO), a commercial-stage biotechnology company focused on developing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has submitted a Conditional Marketing Authorization (CMA) application to the European Medicines Agency (EMA) for VOCERYQ™ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd), previously referred to as INO-3107, as a treatment for adults with RRP.

      16h agoYahoo FinanceINO
      Inovio Pharmaceuticals (INO) Stock Gets Fair Value Boost After VOCERYQ Approval
      Nov 18Yahoo FinanceINO
      Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors
      Nov 16MarketWatchINO
      Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors
      Nov 12MarketWatchINO
      Inovio Pharmaceuticals Inc (INO) (Q3 2026) Earnings Call Highlights: FDA Approval, Commercial ...
      Nov 12Yahoo FinanceINO
      Inovio Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
      Nov 11Yahoo FinanceINO
      Inovio Pharmaceuticals Q3 Earnings Call Highlights
      Nov 11Yahoo FinanceINO
      Inovio: Q3 Earnings Snapshot
      Nov 10Yahoo FinanceINO
      Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day
      Nov 9MarketWatchINO
      Jefferies raises Inovio stock price target on regulatory win
      Nov 6Investing.comINO
      Why is Inovio Pharmaceuticals stock plunging today?
      Nov 6Investing.comINO
      Inovio stock tumbles 25% on $75M share offering
      Nov 6Investing.comINO
      The end of MAHA?; Inovio’s big FDA win
      Nov 6Yahoo FinanceINO
      INOVIO Announces Pricing of Approximately $75 Million Public Offering
      Nov 6MorningstarINO
      Inovio prices $75 million public offering at $1.05 per share
      Nov 6Investing.comINO
      Inovio announces proposed public offering of common stock
      Nov 5Investing.comINO
      INOVIO Announces Proposed Public Offering of its Common Stock
      Nov 5Yahoo FinanceINO
      Inovio: Upgrading To 'Buy' On Voceryq Accelerated Approval RRP And Competitive Advantages
      Nov 4Seeking AlphaINOPGEN
      Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors
      Nov 3MarketWatchINO
      Can Precigen (PGEN) Justify Its Valuation As Inovio Approval Tests Papzimeos?
      Nov 3Yahoo FinanceINOPGEN
      Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day
      Nov 2MarketWatchINO
      INOVIO to Report Third Quarter 2026 Financial Results on November 10, 2026
      Nov 2MorningstarINO
      INOVIO to Participate in Upcoming Scientific Conferences
      Nov 2Yahoo FinanceINO
      Update: Inovio Shares Surge After HC Wainwright Upgrade Following FDA Approval for Voceryq

      (Updates with the latest stock movement and additional details in the first paragraph and headline.)

      Nov 2Yahoo FinanceINO
      Inovio Pharmaceuticals, Inc. (INO) Discusses FDA Accelerated Approval and Commercial Launch of VOCERYQ for RRP - Slideshow (NASDAQ:INO) 2026-11-02

      2026-11-02. The following slide deck was published by Inovio Pharmaceuticals, Inc.

      Nov 2Seeking AlphaINO
      Inovio shares surge 229% as FDA approves first commercial product

      Inovio Pharmaceuticals Inc (NASDAQ:INO) shares jumped 229% to $1.98 after the drug developer said the U.S. Food and Drug Administration granted accelerated approval to VOCERYQ, its first commercial product. The treatment aims to reduce surgeries in adults with recurrent respiratory...

      Nov 2Yahoo FinanceINO
      12 Health Care Stocks Moving In Monday's Intraday Session
      Nov 2BenzingaINO
      INOVIO Receives FDA Accelerated Approval for VOCERYQ to Reduce Surgery Frequency in Adults with RRP
      Nov 2Yahoo FinanceINO
      Why Is Inovio Stock Soaring Today? - Inovio Pharmaceuticals (NASDAQ:INO)
      Nov 2BenzingaINO
      Inovio Wins FDA Approval for VOCERYQ, Its First Commercial Product

      Inovio Pharmaceuticals (NASDAQ:INO) said the U.S. Food and Drug Administration granted accelerated approval to VOCERYQ, formerly known as INO-3107, as a nonsurgical treatment intended to reduce the frequency of surgeries in adults with recurrent respiratory papillomatosis, or RRP. VOCERYQ is the co

      Nov 2Yahoo FinanceINO
      Inovio stock rating upgraded to buy at H.C. Wainwright on FDA approval
      Nov 2Investing.comINO
      12 Health Care Stocks Moving In Monday's Pre-Market Session
      Nov 2BenzingaINO
      This Healthcare Stock Just Soared 200%
      Nov 2Yahoo FinanceINO
      Why is Inovio Pharmaceuticals stock skyrocketing 225% today?
      Nov 2Investing.comINO
      Why Inovio Pharmaceuticals Shares Are Trading Higher By Over 230%; Here Are 20 Stocks Moving Premarket
      Nov 2BenzingaINO
      PGEN Stock Crashes Premarket: Retail Sees Buyout Opening As Inovio Rival Crashes The Party Before Earnings
      Nov 2Yahoo FinanceINOPGEN
      Inovio Pharmaceuticals Gets FDA Accelerated Approval for VOCERYQ
      Oct 30Yahoo FinanceINO
      PGEN Stock Craters 27% After-Hours After Rival Inovio's Rare Disease Drug Receives FDA Approval
      Oct 30Yahoo FinanceINO
      Inovio Pharmaceuticals gets FDA approval for first product
      Oct 30Investing.comINO
      INOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP)
      Oct 30Yahoo FinanceINO
      Why is Inovio Pharmaceuticals stock surging today?
      Oct 30Investing.comINO
      Inovio surges 280% following FDA approval of Voceryq for rare disease (INO:NASDAQ)

      Inovio surges after FDA approves Voceryq for rare HPV-linked recurrent respiratory papillomatosis, marking a first for a DNA-based immunotherapy. Read more here.

      Oct 30Seeking AlphaINO
      Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors
      Oct 30MarketWatchINO
      12 Health Care Stocks Moving In Friday's After-Market Session
      Oct 30BenzingaINO
      US FDA approves Inovio's treatment for rare throat disease; shares surge
      Oct 30Yahoo FinanceINO
      Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors
      Oct 29MarketWatchINO
      Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day
      Oct 28MarketWatchINO
      Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day
      Oct 27MarketWatchINO
      Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors
      Oct 26MarketWatchINO

      This is the newest page. Registered accounts read further back.